Silence Therapeutics priced an upsized public offering expected to raise about $175 million, following favorable Phase 2 pharmacology/primary endpoint results for divesiran in a rare leukemia. The financing is focused on advancing short interfering RNA (siRNA) programs, including divesiran, through later-stage development. The deal consists of 12.96 million American depository shares priced at $13.50 each, with the offering size larger than the company’s earlier plan to raise roughly $150 million. The update signals strong investor appetite after the Phase 2 “best-case” outcome. For the market, the move underscores continued capital support for RNA interference therapies when clinical readouts improve expected value in rare hematologic oncology.